mAbs is a multidisciplinary, open access journal dedicated to the art and science of antibody research and development.
The journal has a strong scientific and medical focus but serves a broad readership, including specialists in technology transfer, legal issues, investment, planning and the regulation of therapeutics.
mAbs covers a range of topics, including:
- Engineering and selection of antibody therapeutics, including antibody-drug conjugates, multispecific andtibodies, and single-domain antibodies
- Machine learning and artificial intelligence applications
- Non-clinical studies of antibodies, such as mechanism of action studies, safety and efficacy studies in animals
- Manufacturing and formulation
- Regulatory review of antibody therapeutics
- Post-approval topics, such as markets
mAbs accepts original research papers, brief reports, short communications, reviews, perspectives, commentaries, meeting reports, and article addenda.
The journal operates a single-anonymized peer review policy.
*Please note that mAbs converted to a fully Open Access journal beginning with Volume 12 (2020). The 2009-2020 volumes will be free to access from 1 January 2021 .
![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/110817/Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
![HRB Open Research is a platform for HRB-funded researchers to rapidly publish their research outputs in an open and accessible way.]({"type":"image" , "src" : "/sda/112432/HRB-KB.jpg"})